Tempus Revenue and Competitors
Estimated Revenue & Valuation
- Tempus's estimated annual revenue is currently $34.4M per year.
- Tempus's estimated revenue per employee is $231,000
- Tempus's total funding is $1.1B.
- Tempus's current valuation is $8.1B.
Employee Data
- Tempus has 149 Employees.
- Tempus grew their employee count by -2% last year.
Tempus Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $33.3M | 95 | -2% | N/A | N/A |
What Is Tempus?
Tempus helps corporate clients navigate global currency markets by combining unparalleled market insight, competitive rates of exchange and unmatched personalized service. We serve thousands of corporate clients by offering these key differentiated features:
keywords:N/A
$1.1B
Total Funding
149
Number of Employees
$34.4M
Revenue (est)
-2%
Employee Growth %
$8.1B
Valuation
N/A
Accelerator
Tempus's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Compliance Officer | Reveal Email/Phone |
2 | Director Pathology and Medical Lab Operations | Reveal Email/Phone |
3 | Operations Specialist | Reveal Email/Phone |
4 | Senior Systems Manager | Reveal Email/Phone |
5 | VP Trading & Dealing | Reveal Email/Phone |
6 | Chief Strategy Officer | Reveal Email/Phone |
7 | CTO | Reveal Email/Phone |
8 | VP OF MARKETING | Reveal Email/Phone |
9 | Executive Director | Reveal Email/Phone |
Tempus News
10 YEARS AGO. April 18, 2012. · In the May 15 Republican primary election for Dist. 1 Idaho County Commissioner position, incumbent R.
NEW YORK Pyramid Biosciences said Tuesday that it will join Tempus' TIME Trial Network for clinical trial patient identification under a...
Pyramid Biosciences Announces TIME Trial Program Collaboration with Tempus for Patients with NTRK Fusion Solid Tumors. April 12, 2022 ·2 min read.
Cancer treatment startup Tempus has raised another mega-round of venture capital funding as it continues to grow as Chicago’s most valuable startup. Tempus raised $200 million in a Series G-2 financing round that included Google, a first-time Tempus investor. Existing investors Baillie Gifford, ...
Chicago-based health tech company Tempus announced it raised $100 million in Series G funding at a post-money valuation of $5 billion Tempus, a Chicago-based health tech company founded by serial entrepreneur Eric Lefkofsky, announced it raised $100 million in Series G funding at a post-money v ...
Other Companies in Washington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $53.3M | 149 | N/A | N/A |
#2 | $15M | 149 | 1% | N/A |
#3 | $22.4M | 149 | 3% | $49.9M |
#4 | $36.1M | 149 | 8% | N/A |
#5 | $36.1M | 149 | N/A | N/A |
Tempus Executives
| Name | Title |
|---|---|
| Juan Carriedo | CEO |
| Andrew Woelflein | Chief Strategy Officer |
| Glenn Kerr | CTO |
| Michael Lindemann | Chief Compliance Officer |
| Ignacio Calles | Chief Financial Officer |
| John Doyle | VP Trading & Dealing |
| Audra Evans | VP OF MARKETING |
| John Hicks | Vice President Sales |